Table 2.
Univariate and multivariate analyses of clinicopathological variables in relation to overall survival in the subcohort of patients with bloods available preoperatively and also at post-12-month
| Clinicopathological features | Univariate analysis | P | Multivariate analysis | P |
|---|---|---|---|---|
| HR (95% CI) | HR (95% CI) | |||
| Age | ||||
| < 60 | Reference | Reference | ||
| ≥ 60 | 2.031 (1.161–3.556) | 0.013 | 1.537 (0.824–2.864) | 0.176 |
| Sex | ||||
| Male | Reference | |||
| Female | 0.586 (0.277–1.243) | 0.164 | ||
| BMI | 0.851 | |||
| BMI < 18.5 | Reference | |||
| 18.5 ≤ BMI < 25 | 1.180 (0.365–3.818) | 0.782 | ||
| BMI ≥ 25 | 1.379 (0.384–4.951) | 0.622 | ||
| ASA score | 0.340 | |||
| 1 | Reference | |||
| 2 | 0.868 (0.492–1.531) | 0.624 | ||
| 3 | 2.168 (0.661–7.117) | 0.202 | ||
| Tumor location | 0.037 | 0.009 | ||
| Upper | Reference | Reference | ||
| Middle | 0.437 (0.198–0.964) | 0.040 | 0.253 (0.104–0.615) | 0.002 |
| Lower | 0.417 (0.207–0.840) | 0.014 | 0.307 (0.138–0.680) | 0.004 |
| Mixed | 0.857 (0.389–1.888) | 0.701 | 0.429 (0.164–1.121) | 0.084 |
| Tumor size (mm) | ||||
| < 50 | Reference | Reference | ||
| ≥ 50 | 2.365 (1.342–4.168) | 0.003 | 0.945 (0.487–1.833) | 0.867 |
| Histologic type | ||||
| Differentiated | Reference | |||
| Undifferentiated | 0.996 (0.523–1.897) | 0.989 | ||
| Vascular invasion | ||||
| Negative | Reference | Reference | ||
| Positive | 2.286 (1.336–3.910) | 0.003 | 1.419 (0.732–2.751) | 0.300 |
| Perineural invasion | ||||
| Negative | Reference | |||
| Positive | 1.738 (0.956–3.158) | 0.070 | ||
| pTNM stage | < 0.001 | < 0.001 | ||
| I | Reference | Reference | ||
| II | 5.866 (0.734–46.911) | 0.095 | 6.164 (0.659–57.680) | 0.111 |
| III | 26.710 (3.678–193.982) | 0.001 | 26.031 (2.850–237.739) | 0.004 |
| Adjuvant chemotherapy* | ||||
| No | Reference | Reference | ||
| Yes | 3.464 (1.474–8.143) | 0.004 | 0.554 (0.198–1.551) | 0.261 |
| LMR change group | < 0.001 | 0.008 | ||
| High LMR to high LMR | Reference | Reference | ||
| High LMR to low LMR | 3.753 (1.892–7.444) | < 0.001 | 2.948 (1.308–6.646) | 0.009 |
| Low LMR to high LMR | 1.080 (0.355–3.281) | 0.892 | 1.239 (0.378–4.056) | 0.723 |
| Low LMR to low LMR | 3.669 (1.782–7.553) | < 0.001 | 3.682 (1.607–8.436) | 0.002 |
CI confidence interval, HR hazard ratio, BMI body mass index, ASA American Society of Anesthesiologists, TNM tumor-node-metastasis, LMR lymphocyte-monocyte ratio, NLR neutrophil-lymphocyte ratio, PLR platelet-lymphocyte ratio, SII systemic immune-inflammation index
*A total of 12 patients missing adjuvant chemotherapy